RPC Boosts Its Portfolio with Acquisition of Peracidin® Product Line from Angelini Pharma

RPC Expands Its Product Portfolio with Strategic Acquisition

In a significant move to enhance its offerings, RPC has announced the acquisition of the Peracidin® product line from Angelini Pharma. This acquisition represents a vital addition to RPC’s portfolio of innovative peroxyacetic/peracetic acid (PAA) sterilants, aimed primarily at the healthcare, water treatment, and life science sectors.

The success of this acquisition is underscored by RPC's commitment to providing high-quality, reliable products and support to its global customer base, which includes healthcare providers and distribution partners. Vern Taaffe, RPC's CEO, remarked, “The acquisition of the Peracidin® product line is an important milestone for RPC and enhances our leadership in peracetic acid technologies. We are excited to expand our reach within the healthcare and water treatment markets, thereby serving our customers better.”

RPC’s dedication to quality and service excellence ensures that Peracidin® customers will receive uninterrupted supply and superior support as they transition to RPC. The legacy of the Peracidin® brand, known for its reliability, will be upheld as RPC aims to further elevate the product's reputation in the industry.

As a leading manufacturer with decades of experience, RPC has established itself as a key player in the dialysis industry. The acquisition is a strategic move that not only broadens RPC's footprint but also enhances its ability to meet diverse customer needs. The company actively engages in initiatives like the Association for the Advancement of Medical Instrumentation (AAMI) to maintain industry standards and improve patient care.

In addition to the new acquisition, the RPC brand is recognized for its technical expertise and commitment to quality. With operations in places like Tucson, Arizona, and Maple Grove, Minnesota, RPC is well-equipped to provide its customers with comprehensive solutions tailored to their specific requirements.

The Peracidin® product line will complement RPC’s existing products, such as their Micro-X® line, creating a robust offering in sterilization and disinfection solutions. RPC is poised to serve a wide array of markets while ensuring that healthcare providers have access to effective and efficient products that enhance patient safety and care.

For those looking to learn more about the Peracidin® product line, RPC encourages reaching out via their contact channels. The company is committed to providing seamless service as it integrates this new product line into its operations.

Overall, this acquisition signifies RPC’s strategic vision for growth and its unwavering commitment to improving healthcare solutions. With a focus on excellence in product quality and customer service, RPC is prepared to lead in the healthcare sector and beyond.